Oncoinvent ASA Sustainability Reports
Oncoinvent ASA is a clinical-stage radiopharmaceutical company developing innovative alpha-emitting therapeutics for solid cancers. Its lead product candidate, Radspherin, targets metastatic cancers within the abdominal cavity.
Sector: Professional & technical services
Country: Norway
Exchange: Oslo Børs
LEI: 213800TYYFXKYF3V2A23
FIGI: BBG002D73RQ4
18 reports from 2015 to 2025
